EXOMIND (BTL-699-2) for the Improvement of Sleep Quality and Reduction of Stress

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-02

Study Completion Date

2026-08-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to evaluate whether the treatment with BTL-699-2 device is able to improve sleep quality and reduce stress in adults above the age of 22 years. The main questions it aims to answer are:

Does the treatment with BTL-699-2 device improve sleep quality? Does the treatment with BTL-699-2 device reduce stress?

Participants will be asked to:

* Undergo six treatments
* Complete the Pittsburgh Sleep Quality Index
* Complete the Perceived Stress Scale Questionnaire
* Complete the Sleep and Stress Assessment Questionnaire
* Complete the Therapy Comfort and Subject Satisfaction Questionnaire

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

EXOMIND (BTL-699) for the Reduction of Food Cravings

NCT06889298

Food Cravings

COMPLETED NA

Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia

NCT06644573

Chronic Insomnia Sleep Deprivation REM Behavior Disorder +34 more

NOT_YET_RECRUITING PHASE1

Efficacy of Melatonin, Low-dose Quetiapine, or Placebo in Patients With Psychiatric Disorders and Comorbid Insomnia

NCT06062953

Psychiatric Disorders Insomnia

RECRUITING PHASE2/PHASE3

A Clinical Trial of De-Stress & Snooze Gummies in Reducing Stress and Insomnia Disorder

NCT06571331

Stress Insomnia Quality of Life

NOT_YET_RECRUITING NA

Characteristics of Sleep Patterns in Young Adults With and Without Insomnia

NCT00177216

Sleep Disorders

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study uses a multi-center, sham-controlled, single-blinded, interventional study design. The subjects will be enrolled and assigned to two experimental study arms - Group A and Group B in the ratio 3:1. Group A will receive active treatment and Group B, which received sham treatment, will serve as a control. All enrolled participants will receive six treatment visits, 3-7 days apart.

The Pittsburgh Sleep Quality Index, Perceived Stress Scale Questionnaire and Sleep and Stress Assessment Questionnaire will be administered to the subjects before the first treatment, after the last treatment, and at the two follow-up visits - 1 month and 3 months after the final session.

The Therapy Comfort Questionnaire will be administered after the last treatment, while the Subject Satisfaction will be given after the last treatment and at both follow-up visits.

The total expected duration of subject participation, from the baseline visit to study completion, is approximately five months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sleep Quality Stress Reduction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

All patients will be randomly divided into 2 study groups - Group A and Group B (sham). The allocation of subjects into study groups will be in ratio 3:1 (Group A:Group B).

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Only the subject will be unaware of the group assignment. The operator providing the treatment will be aware of the subject's group assignment and will perform the treatment with the setting according to the subject's group.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A - active

Group A will receive transcranial magnetic stimulation treatment with the intensity of up to 70% of their motor treshold with the BTL-699-2 device.

Group Type ACTIVE_COMPARATOR

Treatment with BTL-699-2

Intervention Type DEVICE

Six transcranial magnetic stimulation treatments with the BTL-699-2 device will be delivered over the left dorsolateral prefrontal cortex, spaced 3 to 7 days apart. The intensity will be adjusted according to the subject's feedback, up to 70% of the individual's motor threshold.

Group B - sham

Group B will receive transcranial magnetic stimulation treatment with the intensity of 5% of their motor treshold with the BTL-699-2 device.

Group Type SHAM_COMPARATOR

Treatment with BTL-699-2 (sham)

Intervention Type DEVICE

Six transcranial magnetic stimulation treatments with the BTL-699-2 device will be delivered over the left dorsolateral prefrontal cortex, spaced 3 to 7 days apart. The intensity will be adjusted according to the subject's feedback, up to 5% of the individual's motor threshold.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Treatment with BTL-699-2

Six transcranial magnetic stimulation treatments with the BTL-699-2 device will be delivered over the left dorsolateral prefrontal cortex, spaced 3 to 7 days apart. The intensity will be adjusted according to the subject's feedback, up to 70% of the individual's motor threshold.

Intervention Type DEVICE

Treatment with BTL-699-2 (sham)

Six transcranial magnetic stimulation treatments with the BTL-699-2 device will be delivered over the left dorsolateral prefrontal cortex, spaced 3 to 7 days apart. The intensity will be adjusted according to the subject's feedback, up to 5% of the individual's motor threshold.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ExoTMS EXOMIND ExoTMS EXOMIND

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 22 years
* The minimal pre-treatment PSQI score of \>= 5 points
* Ability to determine the motor threshold of the participant. The participant's motor threshold could be established as the minimum stimulus required to induce contraction of the right thumb
* Subjects willing and able to abstain from partaking in any treatments other than the study procedure for the improvement in sleep quality and reduction of stress, including non-invasive brain stimulation treatments other than the study procedure during study participation
* Subjects willing and able to maintain their regular (pre-procedure) diet and exercise regimen without affecting significant change in either direction during study participation
* Willingness to comply with study instructions and to return to the clinic for the required visits
* Women of child-bearing potential\* are required to use birth control measures during the whole duration of the study
* If applicable, subjects will be maintained on pre-study prescribed medications at a stable therapeutic dosage for at least 2 months prior to study entry
* Subject is not using any sleeping medication or is using over-the-counter pills (except Valerian and St. John's Wort) no more than 4 times a week

Exclusion Criteria

* Electronic implants in or near the head - rTMS devices are contraindicated for use in patients who have active or inactive implants in or near the head including device leads, deep brain stimulators, cochlear implants, ocular implants, and vagus nerve stimulators, implanted devices such as cardiac pacemakers, defibrillators, and neurostimulators
* Metallic, ferromagnetic or other magnetic-sensitive implants/objects in or near the head - rTMS devices are contraindicated for use in patients who have conductive, ferromagnetic or other magnetic-sensitive metals implanted in their head (with some exceptions in the mouth - see Operator's Manual) or within 12 in (30 cm) of the therapy coil. (Examples include implanted electrodes/stimulators, aneurysm clips or coils, stents, bullet fragments, jewelry, hair barrettes and tattoos with metallic ink),
* Drug pumps (within 12 in (30 cm) of the therapy coil)
* Application in the heart area
* Persons with a tendency to seizure (hypotonic, epileptic)
* Ongoing anticoagulation therapy
* Ongoing severe or life-threatening condition
* Pulmonary insufficiency
* Heart disorders
* Renal insufficiency
* Decompensated\* hemorrhagic conditions, blood coagulation disorders, cardiovascular diseases
* Malignant tumor, benign tumor
* Fever
* Ongoing pregnancy
* Suicidal tendencies or recent attempt to commit suicide
* Concurrent use of electroconvulsive therapy or vagus nerve stimulation
* Substance-induced depression or depression secondary to a general medical condition
* Seasonal affective disorder
* Substance abuse, obsessive compulsive disorder or post-traumatic stress disorder, major depression
* Psychotic disorder including schizoaffective disorder, bipolar disease or major depression with psychotic features
* Neurological disorders, including a history of seizures, cerebrovascular disease, primary or secondary tumors in CNS, cerebral aneurysm, dementia or movement disorders
* History of increased intracranial pressure or head trauma
* Nursing
* Usage of prescription sleep medication, Valerian of St. John's Wort in the past 2 months
* Usage of over-the-counter pills 5 or more times a week

Minimum Eligible Age

22 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes